PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.35%
Both companies show declining cash positions (-35.35% vs AGEN's -33.74%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-35.35%
Similar yoy growth to AGEN's -33.74%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.32%
Other current assets growth < half of AGEN's -6.71%. David Dodd sees a leaner approach to short-term items.
-30.67%
≥ 1.5x AGEN's -19.27%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-13.90%
Below half AGEN's 2.99%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Less than half of AGEN's 9.17%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-10.42%
Below half of AGEN's 1.74%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
≥ 1.5x AGEN's -11.14%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-10.38%
50-75% of AGEN's -17.41%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
1404.09%
Less than half of AGEN's -95.33%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
10.38%
Below half of AGEN's -14.77%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
-3.56%
Less than half of AGEN's -8.08%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.88%
Less than half of AGEN's 7.19%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-5.58%
Less than half of AGEN's 1.84%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Similar yoy to AGEN's -2.39%. Walter Schloss sees parallel earnings retention vs. competitor.
-5.49%
Above 1.5x AGEN's -3.28%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
-43.19%
≥ 1.5x AGEN's -12.85%. David Dodd sees stronger capital base growth than competitor.
-28.48%
≥ 1.5x AGEN's -11.14%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
14.13%
Less than half of AGEN's -0.04%. David Dodd sees less overall debt expansion vs. competitor.
40.09%
Similar yoy changes to AGEN's 45.02%. Walter Schloss sees parallel net leverage strategies.